Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > Oral Antidiabetic Agents > Flashcards

Oral Antidiabetic Agents Flashcards

1
Q

Typ I Diabetes (6-7 %)

A
  • autoimmunological or idiopathic deletion of pancreatic b cells
    (6-7%) -> absolute insulin deficiency
  • manifestation: childhood (age 4-5) and adolescence (age 12-14
  • No plasma insulin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Typ 2 Diabetes (90 %)

A
  • Insulin resistance
  • manifestation: >40 years
  • normal - high plasma insulin levels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Diabetes mellitus Typ 2 - key facts

A
  1. 347 million people worldwide have diabetes.
  2. In 2012, an estimated 1.5 million deaths were directly caused by diabetes.
  3. More than 80% of diabetes deaths occur in low- and middle-income countries.
  4. WHO projects that diabetes will be the 7th leading cause of death in 2030.
  5. Healthy diet, regular physical activity, maintaining a normal body weight and avoiding
    tobacco use can prevent or delay the onset of type 2 diabetes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Co-Morbidities of T2DM in Germany

A

every
* 12 min one stroke
* 19 min one myocardial infarction
* 19 min one amputation
* 60 min one new dialysis patient
* 90 min one new blind patient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Therapy of Typ-2-Diabetes

A
  1. Wahl Metformin

Monotherapie nach DDG/DGIM bei Metformin-Unverträglichkeit/-Kontraindikationen:
- DPP-4-Inhibitor
- Insulin (häufig Verzögerungsinsulin)
- SGLT-2-Inhibitor
- SUlfonylharnstoff/Glinid
- Glukosidasehemmer
- Pioglitazon

Dritte Stufe: Insulin allein oder Pharmaka-Zweifachkombination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Biguanides in therapy of T2DM

A
  • no lipophilic side chain,
  • no intramolecular hydrogen bridge
  • central amino group is not protonated at physiological pH
    -> lower intracellular concentrations
    -> better tolerability

Bsp: Metformin (Glucophage), Phenformin, Buformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Effects of Metformin

A

GLUCOSE METABOLISM
- lowered gluconeogenesis
- lowered glycogenolysis
- higher glucose uptake (muscle, erythrocytes)
- higher glycogen synthesis

LIPID METABOLISM
- lowered fatty acids oxidation
- lowered LDL and cholesterol in serum
- lowered turnover of fatty acids
- lowered VLDL synthesis
- higher VLDL elimination

OTHERS
- lowered PAI-1, higher fibrinolytic activity
- higher t-PA activity
- lowered AGE
- lowered body weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Discussed mode of actions of Metformin

A
  • decreased gluconeogenesis
  • reduced intestinal glucose resorption
  • increased release of GLP-1
  • increased production of lactate in enterocyten
  • inhibition of „glucagon signaling“
  • Inhibition of glycolytic enzymes
  • decreased transcription of mitochondrial complex I
  • activation of „AMP activated protein kinase“
  • Inhibition of mitochondrionspecific isoform glycerophosphate dehydrogenase D
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Metformin: adverse effects

A

frequency 1/10: gastrointestinal impairmentssustained-release preparation, slow dose increase
frequency 1/10.000: lactacidosis (50% lethal)
* partially metabolized by CYP2C11 and CYP2D1
- careful attention of restrictions on use (renal failure , liver failure, alcohol consumption)
* mainly unchanged eliminated by tubular secretion, t1/2 3h.
- restrictions on use were ignored in 80 % of all registered Methformin induced lactacidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Metformin at renal failure

A
  • Until now, Metformin was contraindicated when creatinine clearance was <45ml/min due to the risk to develop lactacidosis.
  • Based on latest result, the EMA has recommended to use Metformin also in patients with moderate renal failure (state 3b).
  • Recommended maximal daily doses: 2000 mg when GFR is 45-59 ml/min/1,73m2,
    1000 mg when GFR is 30 - 44 ml/min/1,73m2.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Metformin: results from the UKPDS trial

A
  1. Diabetes related end points:
    sudden death, hyper-/hypoglycemia rekated death, myocardial infarction, heart or renal failure, stroke, amputation, retinopathia, getting blind, peripheral vessel disease , bleeding
  2. Diabetes related mortality
    death due to myocardial infarction, stroke, peripheral vessel disease , renal failure, hypo-, hyperglycemia, sudden cardiac death
  3. Total mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sulfonylurea derivatives (SUD): structures

A

BSP: Glibenclamid, Gliquidon, Glimepirid

increase of lipophilicity at R1 -> higher potency
R2: cycloalipathic residues -> higher potency

-> increase insulin release via binding at SUR1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Results from UKPDS trial

A

Important side effects
1. Hypoglycaemia:
Results from the UKPDS trial
2 episodes/y in response to conventional therapy
47 episodes/y after Insulin, 10-30 episodes/y after Glibenclamide

  1. Gain of body weight:
    2.5 kg/Y in response to conventional therapy
    6.5 kg/y after Insulin, 4.2 kg/y after Glibenclamide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Glucosidase inhibitors i

A

Bsp: Acarbose, Miglitol, Voglibose

Therapeutic doses of Miglitol and Acarbose:
* initially: 50 - 100 mg/d
* Dose increase up to 150 - 300 mg/d
* Drug intake: 3xd before meals

side effects:
artery
* flatulence, borborygmus(>10%)
* diarrhoea, abdominal pain (1-10%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Glitazones: mode of action
-> Target genes of PPAR gamma

A
  • Triglyceride hydrolysis: lipoprotein lipase
  • Fatty acid uptake/esterification: CD36, fatty-acid transport protein 1, Fatty acid binding protein 4 (aP2), AcylCoA synthase
  • Lipogenesis and triglyceride synthesis: Phosphoenolpyruvate carboxykinase, Glycerol kinase
  • Lipolysis regulation: Perilipin
  • Adipokines: Adiponectin, Resistin
    Insulin signaling and glucose uptake: Cbl-associated protein, Insulin receptor substarte 2, Glucose transporter 4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Metabolic Effects of Glitazones
-> Thiazolidindione

A

MUSCULATURE
- higher glucose uptake
- higher glycolysis
- higher glycogenolysis
- higher glucose oxidations

ADIPOSE TISSUE
- higher glucose uptake
- higher uptake of fatty acids
- higher lipogenesis
- higher glucose oxidations

LIVER
- lower gluconeogenesis
- lower glucose uptake
- higher glucose uptake
- higher lipogenesis
- higher glycogen synthesis

17
Q

Impact of FFA for insulin resistance

A

MUSCULATURE
- substrate competition
-> lower insulin mediated glucose uptake
-> lower glucose utilisation

PANCREAS
- lipotoxicity
-> decline of beta cell function
-> lower insulin secretion
-> hyperglycemia/dyslipidemia
-> T2DM

LIVER
- higher triglycerid synthesis
- higher glucose production
- lower insulin secretion

18
Q

Cardiovascular effects of Glitazones

A

CONTRACTILITY
- lower Ca2+ influx
- HIGHER [Mg2+]intracellular
- higher vasodilatation

LDL CHOLESTEROL
- lower Small dense LDL
- lower LDL oxidation

COAGULATION
- lower PAI-1

ADHESION
- lower monocyte adhesion
- lower VCAM-1
- lower ICAM-1
- lower plasma E selection

SMC
- lower proliferation
- lower migration
- lower hypertrophy

19
Q

Contraindication sand adverse effects of Pioglitazone

A

CONTRAINDICATIONS
* renal failure
* hepatic dysfunction
* NYHA I-IV
* Insulin therapy
* anaemia
* pregnancy

ADVERSE EFFECTS
* metabolic: higher body weight + Metformin (5.4%) + SUD (5.5%)
- GUT: flatulence
- oedema: 3.5-4 %
- CNS: cephalgia
- hepatic: higher GPT

20
Q

Incretins

A

GLP-1 (glucagon-like peptide-1) and GIP (glucose dependent insulinotropic polypeptide) are GUT hormones, being responsible to induce higher insulin release after oral glucose administration compared to i.v. injection.
-> The incretin effect is reduced in T2DM

21
Q

GLP-1 is metabolized by Dipeptidylpeptidase IV (DPP-IV)

A

Cleavage of dipeptide when proline or alanine residue at 2nd position of amino acid sequence
His1-Asp2-Glu3-Phe4-Glu5-Arg6-His7–Ala8–Glu9–Gly10–Thr11–Phe12 -
-> (GLP-1) His7–Ala8–Glu9–Gly10–Thr11–Phe12 -
-> Glu9–Gly10–Thr11–Phe12 -

22
Q

Incretin analogues
-> Exenatide (Byetta)

A
  • Half life 2.5 h
  • hypoglycemia in combination with SUD
  • antibodies (44 %, 6% with high titers, 3 % with reduced efficacy)
  • 53 % homology
23
Q

Liraglutide, a humanized GLP-1 analogue

A

high homology (97%) compared to human GLP-1 -> lower AB
-> no reduced efficacy due to liraglutide related AB

Among overweight or obese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate and liraglutide, compared with placebo, were each associated with achieving at least 5 % weight loss at 52 weeks. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 % weight loss.

24
Q

Liraglutide, a humanized GLP-1 analogue

A

high homology (97%) compared to human GLP-1 -> lower AB
-> no reduced efficacy due to liraglutide related AB

25
Q

Cardiovascular effects of GLP-1

A

HEART
- lower inflammation
- higher glucose uptake
- lower ischemic injury
- higher LV function
- higher heart rate

VASCULATURE
- lower inflammation
- higher endothelial function
- higher vasodilation
- higher plaque stability
- higher blood flow
- lower smooth muscle proliferation
- lower platelet aggregation

26
Q

New developments of GLP-1 analogues

A

EXENATIDE
- homology: 53 %
- T1/2: 2.5 h

LIXISENATID
- homology: 53 %
- T1/2: 3 h
- withdrawal

LIRAGLUTID
- homology: 97 %
- T1/2: 24 h

DULAGLUTID
- homology: recombinant GLP-1 fusionprotein
- T1/2: 4.7 d

ALBIGLUTID
- homology: DPP-IV resistant GLP-1 dimer fused to human albumin
- T1/2: 5 d
- withdrawal

27
Q

DPP-IV inhibitors

A

COMPETITIVE
Sitagliptine (Januvia®)
Vildagliptine (Galvus®, withdrawn 2014)
Linagliptine (Trajenta®, not available)
NON COMPETITIVE
Saxagliptine (Onglyza®)

28
Q

Adverse effects (pf Sitagliptine)

A
  • cold,diarrhoea,pharyngitis,headache,arthralgia
  • insomecasesaftermarketrelease:anaphylaxis,angioedemaandskinirritation. * Lessselectivity?
    – Beside GLP-1 and GIP other substrates (e.g. PACAP, trypsinogen, procolipase, somatoliberin, GLP-2, NPY) also contain a proline residue at the correct position enabling these peptides for DPP-4 degradation. The consequences of a reduced metabolism of these peptides is not known.
    – DPP-4 inhibitors also block DPP-8 and DPP-9. The clinical relevance of blocking DPP-8/-9 is not known.
    – DPP-4 is also involved in regulation of other biological functions (e.g. immune reactions, cell adhesion). Considering the presence of DPP-4 in various cell types and also in blood cells, GLP-1 independent effects are assumed to be of clinical relevance.
29
Q

Sodium-glucose-co-transporter (SGLT)

A

When SGLT1 is blocked, more glucose remains in the lumen of the intestine being eliminated. Plasma glucose is indeed reduced, but higher GUT levels induced GUT related adverse effects (diarrhea).

When SGLT 2 is blocked, more glucose will be renally eliminated. This indeed decreases blood glucose but also induce caloric loss and reduction of blood pressure (by osmotic diuresis). Both effects are beneficial.

In Germany, Canagliflozin is withdrawn (2014).

30
Q

Blocking the renal glucose reabsorption by SGLT-2 inhibitors

A
  • but SGLT 2 is mainly (90%) responsible for renal glucose reabsorption
  • However, using SGLT-2 knock out mice, glucose reabsorption was 40 %, thus indicating that the impact of SGLT-1 for glucose reabsorption is more than 10%. These results suggest that the contribution of SGLT1 to renal glucose reabsorption is greater under lower glycemic conditions than under hyperglycemic conditions.
  • These results suggest that SGLT2-selective inhibitors pose a lower risk of hypoglycemia than SGLT1/2 inhibitors.
31
Q

FDA strengthens kidney warnings for diabetes medicine canagliflozin (Invoking, Invokamet) and dapagliflozin

A

The U.S. Food and Drug Administration (FDA) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Based on recent reports, we have revised the warnings in the drug labels to include information about acute kidney injury and added recommendations to minimize this risk.
From March 2013, when canagliflozin was approved, to October 2015, FDA received reports of 101 confirmable cases* of acute kidney injury, some requiring hospitalization and dialysis, with canagliflozin or dapagliflozin use (see Data Summary). This number includes only reports submitted to FDA, so there are likely additional cases about which we are unaware. In approximately half of the cases, the events of acute kidney injury occurred within 1 month of starting the drug, and most patients improved after stopping it. Some cases occurred in patients who were younger than 65 years. Some patients were dehydrated, had low blood pressure, or were taking other medicines that can affect the kidneys.
We urge health care professionals and patients to report side effects involving canagliflozin, dapagliflozin, or other medicines to the FDA MedWatch program, using the information in the “Contact FDA” box at the bottom of the page.

32
Q

eGFR during therapy with Empagliflozin

A
  • SGLT-2 inhibition reduces hyperfiltration via TGF
33
Q

Risk of diabetic Ketoacedosis after Initiation of an SGLT2 inhibitor

A

Case reports have suggested that SGLT2 inhibitors may be associated with an increased risk of diabetic ketoacidosis, which led to a warning from the FDA in May 2015. The objective of our study was to assess the risk of diabetic ketoacidosis after the initiation of an SGLT2 inhibitor.
In conclusion, shortly after initiation, SGLT2 inhibitors were associated with approximately twice the risk of diabetic ketoacidosis as were DPP4 inhibitors, although cases of diabetic ketoacidosis leading to hospitalization were infrequent. The increased risk of diabetic ketoacidosis with SGLT2 inhibitors is among the factors to be considered at the time of prescribing and throughout therapy if patients present with symptoms suggestive of diabetic ketoacidosis.

Leber: higher Ketogenesis
Niere: higher Glucosuria

Pharmacology (22 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions